Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup
Amyloid imaging related abnormalities (ARIA) have now been reported in clinical trials with
multiple therapeutic avenues to lower amyloid-β burden in Alzheimer's disease (AD). In …
multiple therapeutic avenues to lower amyloid-β burden in Alzheimer's disease (AD). In …
Cerebral microbleeds: a review of clinical, genetic, and neuroimaging associations
Cerebral microbleeds (microbleeds) are small, punctuate hypointense lesions seen in T2*
Gradient-Recall Echo (GRE) and Susceptibility-Weighted (SWI) Magnetic Resonance …
Gradient-Recall Echo (GRE) and Susceptibility-Weighted (SWI) Magnetic Resonance …
MR imaging features of amyloid-related imaging abnormalities
J Barakos, R Sperling, S Salloway… - American Journal …, 2013 - Am Soc Neuroradiology
BACKGROUND AND PURPOSE: AD is one of the few leading causes of death without a
disease-modifying drug; however, hopeful agents are in various phases of development. MR …
disease-modifying drug; however, hopeful agents are in various phases of development. MR …
Vascular alterations in PDAPP mice after anti-Aβ immunotherapy: implications for amyloid-related imaging abnormalities
W Zago, S Schroeter, T Guido, K Khan, P Seubert… - Alzheimer's & …, 2013 - Elsevier
Background Clinical studies of β-amyloid (Aβ) immunotherapy in Alzheimer's disease (AD)
patients have demonstrated reduction of central Aβ plaque by positron emission tomography …
patients have demonstrated reduction of central Aβ plaque by positron emission tomography …
First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to …
M Delnomdedieu, S Duvvuri, DJ Li, N Atassi… - Alzheimer's research & …, 2016 - Springer
Abstract Background In the First-In-Human (FIH), 39-week, randomized, adaptive design
study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with …
study, safety, tolerability, pharmacokinetics and biomarkers were measured in patients with …
Alzheimer's association prompts FDA to broaden trials
KJ Bender - Psychiatric Times, 2011 - go.gale.com
The Alzheimer's Association announced in July that the FDA had accepted its
recommendations to modify exclusion and monitoring criteria for clinical trials of agents that …
recommendations to modify exclusion and monitoring criteria for clinical trials of agents that …